ArticleThe Journal of clinical investigation2025

Co-targeting TGF-β and PD-L1 sensitizes triple-negative breast cancer to experimental immunogenic cisplatin-eribulin chemotherapy doublet.

Laura Kalfeist et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.